Lucid Diagnostics Inc (LUCD)
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on detecting esophageal precancer and cancer in the United States. The company serves patients with gastroesophageal reflux disease, or GERD, who face an elevated risk of developing esophageal adenocarcinoma, a serious form of esophageal cancer. Its core offering is the EsoGuard Esophageal DNA Test, which is used with the EsoCheck Esophageal Cell Collection Device to obtain samples for testing. Lucid Diagnostics was incorporated in 2018 and is headquartered in New York, New York. It operates as a subsidiary of PAVmed Inc., and its common stock is listed on the NASDAQ exchange under the symbol LUCD.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LUCD
|
$0.78
|
-19.1% Downside
|
Overvalued
|
$3.95
|
308.4% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-3.2x
|
-30.2x
|
36.1x
|
184.9 M
|
192.9 M
|
12.1%
|
73.7%
|
-13.2
|
—
|
79.8%
|
